Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18

Next Previous
X
Search
Trial Profile

EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mosedipimod (Primary)
  • Indications Febrile neutropenia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Enzychem Lifesciences Corporation

    • Most Recent Events

    • 10 Aug 2023 Phase of the trial is changed from phase 1 to phase 1/2. Number of treatment arms have been increased from 4 to 6 by the addition of experimental cohorts 5 and 6 for the study drug doses of 3000 mg and 4000 mg respectively. Upper age limit of 85 years is removed from inclusion criteria.
    • 10 Aug 2023 Status changed from recruiting to completed.
    • 30 Oct 2019 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top